

Novel chemical- and protein-mediated methods for glucosamine detection

Linshu Chen¹, Pedro Laborda¹, Zhipeng Cai¹, Andrew Kevin Hagan¹, Aimin Lu², Josef Voglmeir¹, and Li Liu^{1*}

¹ Glycomics and Glycan Bioengineering Research Center (GGBRC), College of Food Science and Technology, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, People's Republic of China

² College of Sciences, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, People's Republic of China

* Corresponding author, E-mail: lichen.liu@njau.edu.cn

Abstract

We describe two novel approaches for the determination of glucosamine (GlcN). The first approach is based on the chemical derivatization of GlcN with the non-fluorophor 1,3-diphenyl-1,3-propanedione (DPPD), which results in a condensation product with interesting fluorescent properties. The obtained compound was isolated by silica-gel chromatography and its structure elucidated by NMR and mass spectrometry. The second approach is based on a previously undescribed sensitivity of the enzyme glucosamine-6-phosphate deaminase (GPDA) towards GlcN, which resulted in the precipitation of the enzyme. Using a rational enzyme engineering approach and both liquid-based and plate-based screening methods, mutational GPDA variants with significantly improved precipitation properties were identified and characterized. These novel glucosamine detection methods may be a useful addition to the repertoire of currently available glucosamine detection sensors.

Citation: Chen L, Laborda P, Cai Z, Hagan AK, Lu A, et al. 2022. Novel chemical- and protein-mediated methods for glucosamine detection. *Food Materials Research* 2:19 <https://doi.org/10.48130/FMR-2022-0019>

INTRODUCTION

Glucosamine (2-amino-2-deoxy-d-glucose, GlcN), an important amino sugar, which is found in almost all organisms, including bacteria, fungi, and animals, with shrimp and crab shells being particularly rich in this compound^[1]. GlcN has a wide range of applications in the biomedical, food, and cosmetic industries^[2,3]. This compound is believed to be a beneficial food supplement for the treatment of osteoarthritis by aiding cartilage growth and repair, and therefore GlcN has become a popular non-prescription nutritional supplement with a currently estimated market volume of \$USD 935M in 2022, and it will likely surpass the \$USD 1B mark in 2026^[4]. GlcN is used as a functional food additive to improve joint health, and in the cosmetics industry as an additive to skin moisturizers^[5,6]. In addition, several reports convincingly demonstrated that GlcN has anti-proliferative effects against certain types of cancer which makes GlcN an interesting compound for novel medical therapies^[7–11]. Another beneficial feature of GlcN is that it can extend the lifespan of model organisms such as *C. elegans* and mice *via* autophagy and mitochondrial biogenesis^[12,13]. For these reasons, a method for the selective detection of GlcN would be an extremely useful tool for research on this carbohydrate. For example, novel approaches to determine glucosamine during the processing of food waste such as shrimp shells^[14,15], or the early clinical diagnosis of GlcN to better understand its role in diseases may be of keen interest^[16,17]. Herein, we describe two novel derivatization- and protein-mediated methods for glucosamine detection. To our knowledge, only a few fluorescent GlcN sensors have been previously described^[18–21], and

no specific protein-based precipitation method sensitive to GlcN has yet been reported.

MATERIALS AND METHODS

General

All reagents and chemicals were used as received from commercial suppliers without further purification or modification. Silica gel TLC plates were obtained from Merck KG (Type 60 F254, Darmstadt, Germany). Nickel-nitrioltriacetic acid Sefinose Resin was purchased from BBI Life Sciences (Shanghai, China). NMR spectra were generated on a Bruker AV-400 instrument using the residual solvent signal as the internal standard. Chromatographic analyses were performed by a Shimadzu LCMS 2020 system (Shimadzu Corporation, Kyoto, Japan).

Synthesis of the fluorogenic glucosamine derivative

Glucosamine hydrochloride (539 mg, 2.5 mmol), 1,3-diphenyl-1,3-propanedione (DPPD, 560 mg, 2.5 mmol), sodium bicarbonate (42 mg, 0.5 mmol) and 5 mL of methanol (MeOH)/H₂O (3:1) were combined and mixed in a 50 mL sealable glass tube. The tube was heated to 110 °C for 17 h. The reaction mixture was allowed to cool to room temperature and dried under reduced pressure. The solid residue was dissolved in MeOH and mixed with 1 g of silica, then dried again. The mixture was loaded onto the silica column, which was then eluted with MeOH/CHCl₃ (5:95). All fractions were analyzed by thin-layer chromatography (TLC, 1:9, MeOH/CHCl₃) at 254 nm and 362 nm, and fractions containing the fluorescent product ($R_f = 0.7$) were pooled together

and lyophilized. The dry samples were re-dissolved in H₂O and purified on reversed-phase C18 SPE cartridges (Supelco-5706, 500 mg bed weight). The C18 reversed-phase cartridges were preconditioned with acetonitrile (ACN) and equilibrated with water. The samples were applied to the cartridges followed by washing with water, and the cartridges were successively eluted with water (10:90), ACN/water (50:50), and ACN. Fractions were analyzed by TLC, and the fluorescent products ($R_f = 0.7$) were pooled together and lyophilized (yielding 8 mg).

¹H NMR (400 MHz, MeOD): δ 2.16 (1H, dd, *J* 14, 2, H5''(Z)), 2.28 (1H, dd, *J* 13.2, 6, H5'(E)), 2.44–2.56 (1H, m, H5'(Z)) 2.48 (2H, dd, *J* 13.6, 6, H5''(E)), 3.63–3.80 (2H, m, H8', H8''), 4.17 (1H, app q, *J* 4.8, H7(Z)), 4.30 (1H, td, *J* 4.8, 2.4, H7(E)), 4.47 (1H, td, *J* 6, 4.8, H6(Z)), 4.54 (1H, dt, *J* 6, 2.4, H4(E)), 5.48 (1H, s, H4(Z)), 5.53 (1H, s, H4(E)), 7.60–7.54 (2H, m, H2), 7.68–7.62 (1H, m, H1), 7.88–7.84 (2H, m, H3).

¹³C NMR (100 MHz, MeOD): δ 203.64 (C8(Z)), 202.60 (C8(E)); 178.58 (C5(Z)), 177.91 (C5(E)); 134.20 (C1); 134.16 (C4); 130.21 (C2); 128.63 (C3); 97.25 (C7(E)), 96.42 (C7(Z)); 93.43 (C6(E)), 92.86 (C6(Z)); 90.99 (C11(E)), 89.66 (C11(Z)); 73.90 (C10(E)), 73.14 (C10(Z)); 63.91 (C12(E)), 63.20 (C12(Z)); 44.41 (C9(E)), 42.20 (C9(Z)).

HPLC analysis

Chromatographic analyses were carried out using a Shimadzu LCMS 2020 system (Shimadzu Corporation, Kyoto, Japan) consisting of an LC-30AD pump equipped with a low-pressure gradient mixing unit, a SIL-30AC autosampler, an RF-20Axs fluorescence detector (excitation 362 nm, emission 450 nm), and an ESI mass spectrometer. The analytes were separated on a reversed phase HPLC column (Phenomenex Hyperclone 5 μ m ODS 120 Å, 250 \times 4.6 mm). The mobile phases were NH₄COOH (pH 4.5, 50 mM) in water and acetonitrile for solvents A and B, respectively. The flow rate was 1.5 mL/min. After injection of 5 μ L of the sample, a linear gradient of 12%–45% B was applied from 0 to 3 min; B was then increased to 95% over 1 min and held at 95% for 2 min. B was then decreased to 12% over 1 min, and the column was equilibrated with the initial conditions for 3 min.

Plasmid construction, expression, and purification of GPDA

A putative glucosamine-6-phosphate deaminase gene from the bacterium *Enterococcus canintestini* (GenBank Accession Number WP_071864541.1) containing Nde I and Xho I restriction site overhangs was synthesized and ligated on the pET30a vector by Tsingke Biotechnology Company (Nanjing, China). The constructed expression vector was transformed into *Escherichia coli* BL21 (DE3) competent cells and plated on lysogeny broth (LB) agar containing 50 μ g/mL kanamycin. A single colony was transferred into a 2 L Erlenmeyer shaking flask containing 400 mL of LB medium and shaken at 37 °C until the culture density reached an absorbance at $\lambda = 600$ nm of 0.5. The final concentration of 1 mM isopropyl 1-thio- β -D-galactopyranoside (IPTG) was added to start the recombinant protein expression. After 20 h of induction at 18 °C, the biomass of the fermentation culture was pelleted by centrifugation at 5,000 g for 20 min. The cell pellet was re-suspended in 10 mL of lysis buffer (100 mM NaCl, 50 mM Tris, 1% (w/v) Triton X-100, 1 mM PMSF, adjusted

to pH 8.0) and sonicated for 20 min. The cell homogenate was cleared by centrifugation (20 min at 12,000 g) and then the supernatant was subject to nickel-nitrilotriacetic acid (Ni-NTA) column chromatography (5 mL of bed volume). Unspecifically bound proteins were washed off the Ni-NTA column with 150 mL of WB-solution (consisting of 50 mM NaCl, and 50 mM Tris, adjusted to pH 8.0 with HCl), and the target protein was eluted with 10 mL of EB-solution (WB-solution containing 500 mM imidazole). The purity and quantity of recombinant GPDA was estimated by SDS-PAGE, and samples were subsequently stored at –80 °C for further experiments.

GPDA mutant library design

Two different approaches were taken for the generation of mutant libraries. The first approach was to generate a randomized GPDA mutant library by error-prone PCR based on the method described by Lin-Goerke et al.^[22] In brief, the pet30a-GPDA plasmid (10 ng/ μ l) was used as a template for amplification of the PCR product using the T7 forward/reverse primers (Supplemental Table S1). The 2 \times Taq Polymerase Master Mix (Vazyme, Nanjing, China) was supplemented with 0.8 mM of additional dCTP/dTTP, and 100 μ M MnCl₂, which resulted in an error rate of ~1 mutation/700 base pairs.

The second approach was to generate focused^[23] GPDA mutant libraries through the simultaneous randomization of three conserved amino acids adjacent to the substrate binding pocket of the NagB/GlcN6P crystal complex from *S. mutans* (PDB accession 2R11)^[24]. These amino acids were then randomized with the QuickChange XL site-directed mutagenesis protocol (Stratagene) by replacing the three conserved amino acid codon triplets with an 'NDTNDTNDT' nucleotide sequence using primer pairs bearing this randomized sequence motif (Supplemental Table S1). The mutated plasmids were verified by DNA sequencing and transformed into *Escherichia coli* BL21 (DE3) competent cells for performing the in-solution and colony screening assays.

GPDA mutant screen

The screening assays for GPDA precipitation mutants were conducted with both liquid and membrane-based screening methods. For the liquid screening assay, a modified M9 minimal growth medium which was sterilized and prepared according to the description by Elbing & Brent^[25] consisted of Na₂HPO₄·12H₂O (17.1 g/L), KH₂PO₄ (3 g/L), NaCl (0.5 g/L), NH₄Cl (1 g/L), MgSO₄ (240 mg/L, heat-sterilized separately), CaCl₂ (11.1 mg/L, heat-sterilized separately), isopropyl thio- β -galactoside (IPTG, 23.8 mg/L, filter-sterilized separately), and glucosamine (5 g/L, filter-sterilized separately). Five mL of minimum growth medium were transferred into glass vials and 5 μ L of each *E. coli* BL21 (DE3) mutant library were shaken for 12 h at 37 °C. Then, 20 μ L of each culture (OD₆₀₀ < 0.05) were transferred into fresh vials containing 5 mL of minimum medium and shaken for another 12 h at 37 °C. This procedure was repeated seven times, with passages 5–7 showing an obvious cell growth after the 12 h incubation (OD₆₀₀ > 0.5). From each final incubation vial, 200 μ L of 10^{–4}-dilutions were transferred onto LB agar plates (9 cm diameter), which resulted after 16 h incubation at 37 °C in 400–600 colonies/plate. Three colonies from each library were picked for identifying the selected mutants by Sanger sequencing.

Novel GlcN detection methods

For the membrane-based GPDA precipitation screen, 200 μL of 10^{-4} -dilutions of each mutant libraries were incubated on circular mixed cellulose ester (MCE) membranes (0.1 mm thickness, 0.45 μm pore size) located on LB agar plates (9 cm diameter). After 6 h incubation at 37 $^{\circ}\text{C}$, the MCE membranes were transferred onto 9 cm petri dishes containing solid minimum medium (medium supplemented with 10 g/L agarose and 71.4 mg/L IPTG) and incubated for 16 h at 37 $^{\circ}\text{C}$. The colonies were then visualized using a solidified MTT reaction mixture in 9 cm petri dishes (consisting of 5 mg MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) and 100 mg agarose in 10 mL of phosphate-buffered saline solution). Dark enlarged colonies were selected for mutational analysis by Sanger sequencing.

GPDA mutant variant characterization and protein modeling

Selected GPDA variants were expressed in recombinant form and purified as described above. The purified GPDA variants (typically 40 μL) were then incubated with 40 μL of a 100 mM GlcN solution, and the protein precipitation was monitored at 340 nm using the method described by Shmueli et al.^[26] using a 384-well-microplate reader (Thermo Multiskan). The three GPDA mutant variants which showed the highest precipitation rate were then further tested for their precipitation behavior when exposed to glycine or a series of other carbohydrates (glucose, N-acetylglucosamine, mannose, galactose, fructose, 50 mM final concentration). In addition, protein precipitation was also analyzed at different GlcN concentrations (final GlcN concentration between 1 mM and 200 mM). The structural models of the apo-forms of the GPDA wild-type and mutant variants were generated using the AlphaFold tool of the ChimeraX software package (Version 1.5rc)^[27]. GlcN was modeled into the active site of the GPDA variants using the molecular scaffold of glucosamine-6-phosphate shown in complex with PDB 2RI1^[24] and replacing the phosphate moiety with a hydroxyl group in a similar manner as previously described by Hu et al.^[28] GPDA variants were overlaid using the MatchMaker tool of the Chimera software package (Version 1.16)^[29].

RESULTS AND DISCUSSION

Chemical derivatization of GlcN

Our research group reported previously an efficient strategy for the labeling of mono- and oligosaccharides containing 2-hydroxyl groups using non-fluorescent 1,3-di(2-pyridyl)-1,3-propanedione as the derivatization reagent^[30,31]. These works allowed the synthesis of a fluorescent 2-pyridyl-furan derivative *via* Knoevenagel condensation between 1,3-di(2-pyridyl)-1,3-propanedione and the reducing end of a carbohydrate followed by intramolecular oxa-Michael cyclization. Applying similar reaction conditions as reported before, the treatment of GlcN with 1,3-diphenyl-1,3-propanedione (DPPD) in the presence of sodium hydrogen carbonate led to highly fluorogenic *cis/trans* isomers (compounds **1a** and **1b**, Fig. 1a). Thin-layer chromatography (TLC) revealed these compounds **1a** and **1b** as a single spot when the plate was irradiated with UV light (Fig. 1b). The synthesized compounds were also observed by HPLC analysis using a fluorometric




Fig. 1 Characterization of the fluorescent glucosamine derivative. (a) Isolated compound **1a** and **1b** mixture after silica-gel chromatography purification. (b) TLC analysis by irradiation with UV light (left: 362 nm, right: 254 nm). (c) HPLC chromatogram of compounds **1a** and **1b** (excitation 362 nm, emission 450 nm). (d) Positive ion electrospray-ionization (ESI) mass spectrum of compounds **1a** and **1b**.

detector (retention time: 4.2 min, Fig. 1c), confirming the fluorescent nature of the glucosamine derivative. As shown in Supplemental Fig. S1, HPLC-based analysis of the obtained compound demonstrated excitation and emission maxima at wavelengths of 362 nm and 450 nm, respectively. Interestingly, the excitation wavelength appears in the UV whereas the emission wavelength is inside the visible light, producing a violet/blue color. The unusually large difference between recorded excitation and emission wavelengths, 88 nm, makes this compound a fascinating small dye.

Silica-gel chromatography purification allowed the isolation of the fluorescent compound as a light yellow solid (Fig. 1a). The structure of the new compound was elucidated by NMR (Supplemental Figs S2–S7). NMR analysis indicated that the isolated mixture was composed of compounds **1a**(E) and **1b**(Z) in a 2:1 ratio. The measured m/z value of glucosamine derivatives **1a** and **1b** ($[M+H]^+ = 262.0$) compared well with the calculated mass ($[M+H]^+ = 262.1$) (Fig. 1d). The signal corresponding to H4 of **1a** appears at 5.53 ppm whereas the H4 proton in **1b** generates a signal at 5.48 ppm, indicating that **1a** is the (E) isomer judging from previously reported

NMR data for enolates^[32]. To elucidate the size of the ring (possible structures as shown in Supplemental Fig. S8), an NMR analysis based on the angles/coupling constants, Karplus equation, between vicinal ring protons was performed. A 7.2 Hz coupling constant (corresponding with an angle of about 150°–160°) was previously reported for vicinal *trans* protons in a similar unsaturated 7-membered ring whereas the signal corresponding to H7 appears in our spectrum as an apparent triplet of doublets with coupling constants of 4.8 and 2.4 Hz in the case of the **1a** and as an apparent quartet a coupling constant of 4.8 Hz in the case of the **1b**, indicating that we can discount this possibility^[33]. This result is in agreement with the HMBC spectra wherein there are only correlations between both H6 and H7 and C7 and not between H8' and H8'' and C7. Coupling constants of *trans* vicinal protons in unsaturated 6-membered ring structures (unsaturated rings with two sp² carbons should have similar conformations to our conjugated system), such as D-glucal or other unsaturated derivatives^[34,35] are about 9–11 Hz (corresponding with an angle of almost 180°) which is not in

agreement with the coupling constants observed for H7 suggesting that a structure incorporating a 6-membered ring can be discounted. The signal corresponding to H6 appears as an apparent doublet of triplets with coupling constants of 6 and 2.4 Hz for **1a** or as an apparent triplet of doublets with coupling constants of 6 Hz and 4.8 Hz in compound **1b**. The *trans* vicinal protons of 2,3-dihydrofuran derivatives show a coupling constant of 6–8 Hz (corresponding with an angle of about 150°) whereas *cis* vicinal protons show a coupling constant of about 4.5 Hz (corresponding with an angle of 30°–40°) which is consistent with the results observed in our ¹H NMR spectrum for H6 indicating that **1a/1b** is a 5-membered ring^[36].

The synthesis of **1** can be explained through the mechanism shown in Fig. 2. After Knoevenagel condensation between DPPD and the reducing end of GlcN to produce **2**, the 5-membered ring **3** is formed by intramolecular oxa-Michael cyclization. The irreversible, base-promoted decarboxylation of **3** then results in compound **4**^[37]. Then, compound **4** is oxidized by an unknown oxidant (presumably molecular




Fig. 2 Reaction of GlcN with DPPD to afford fluorescent glucosamine derivatives **1a** and **1b** with atom numbering corresponding to that used for NMR assignment.

oxygen in the alkaline environment) at the carbonyl group forming α,β -unsaturated carbonyl compounds **5a/5b**. Then, the dehydration of compounds **5a/5b** results in the formation of the **1a/1b** mixture. Finally, the labeling of GlcN with different propane-1,3-dione derivatives, such as 1,3-dipyridin-2-ylpropane-1,3-dione, dibenzoylmethane, and 1-benzoyl-3,3,3-trifluoroacetone, and the ester ethyl benzoylacetate, was also studied (Supplemental Fig. S9). All reactions were examined by TLC analysis. UV-active compounds with R_f values similar to that observed for **1a/1b** could be detected when 1,3-dipyridin-2-ylpropane-1,3-dione, dibenzoylmethane and ethyl benzoylacetate were used as the labeling reagents whereas no UV-active compounds were detected after the labeling with 1-benzoyl-3,3,3-trifluoroacetone. The blue/violet color of the dot when the TLC plate was irradiated with a 362 nm light indicated the formation of a fluorescent derivative.

Protein-mediated detection of GlcN by GPDA

Protein-mediated detection of carbohydrates was first described in the late 19th century, showing that protein extracts from plants were able to agglutinate red blood cells depending on their cell surface carbohydrates^[38]. However, this phenomenon usually requires a multivalent binding mode of the same carbohydrate moieties to various individual binding sites of the protein units to trigger protein precipitation *via* the formation of an insoluble three-dimensional carbohydrate-protein network^[39]. So far, sugar moieties which can precipitate lectins and are not organized in larger oligomeric branched structures such as natural glycoconjugates^[40] or artificial glycodentrimers^[41] were not yet reported. Therefore, lectins may not be suitable for the detection of monomeric carbohydrates. We observed that GPDA, which is an enzyme that catalyzes the conversion of glucosamine 6-phosphate into fructose 6-phosphate and ammonium, showed a peculiar precipitation behavior in the presence of the monosaccharide GlcN (Fig. 3a). The addition of other monosaccharides such as glucose, N-acetylglucosamine, mannose, galactose, or fructose did not result in any observable GPDA precipitation (Supplemental Fig. S10a). However, the GPDA precipitation required incubation times of several hours, and therefore we attempted to engineer the glucosamine 6 phosphate binding site of GPDA to increase its precipitation performance. This type of mutational approach was previously reported for changing the binding specificity of ACG, a carbohydrate binding protein specific for β -galactosides, which changed its carbohydrate binding profile to α 1,3-linked GalNAc after the substitution of an asparagine with alanine at position 46 (Asn46Ala)^[42]. Therefore, one random mutation library (generated by error-prone PCR, ~900 clones) and two focused libraries mutating amino acids $^{36}G^{37}S^{38}T$ and $^{124}G^{123}Y^{126}N$ (generated by site directed mutagenesis using the primers listed in Supplemental Table S1, ~700 clones each). These three libraries were transformed into the BL21(DE3) expression host and GPDA mutants which had a faster growth rate were selected in eight passes by the liquid medium screening method described above. This resulted in the isolation of two individual GPDA variants with the amino acid substitutions $^{36}F^{37}R^{38}I$ or $^{124}N^{123}Y^{126}N$. Applying the three mutant libraries to the membrane-based GPDA precipitation




Fig. 3 Characterization of GPDA wild-type and mutant variants. (a) Precipitation behavior of wild-type GPDA in the presence of various concentrations of GlcN. (b) Protein sequence comparison of the selected GPDA mutant variants. (c) Comparison of protein yields of GPDA mutant and wild-type variants. (d) Precipitation behavior of the GPDA variants in the presence of 50 mM GlcN.

assay, which selected mutant variants with precipitation activity based on the size of the colonies (Supplemental Fig. S11), GPDA variants $^{36}F^{37}H^{38}L$, $^{36}V^{37}Y^{38}Y$, $^{36}V^{37}V^{38}V$, $^{36}F^{37}R^{38}I$, and ^{46}I (from the error-prone PCR derived library) were selected (Fig. 3b). To rule out that the increased growth performance of the mutant variants was due to spontaneous mutations in the BL21(DE3) expression host's genomic DNA, the plasmids of all GPDA mutant variants were re-transformed into fresh BL21(DE3) cells.

Generally, the GPDA mutant variants showed comparable expression levels to the wild-type variant (Fig. 3c), with the exception of GPDA variant $^{36}F^{37}H^{38}L$, which showed slightly

reduced expression levels. The precipitation behavior of the purified GPDA variants in the presence of 50 mM GlcN showed that mutants $^{36}\text{F}^{37}\text{H}^{38}\text{L}$, $^{36}\text{Y}^{37}\text{Y}^{38}\text{Y}$, and $^{124}\text{N}^{123}\text{Y}^{126}\text{N}$ precipitated significantly faster compared to the GPDA wild-type and other mutant variants (Fig. 3d). Therefore, these $^{36}\text{F}^{37}\text{H}^{38}\text{L}$, $^{36}\text{Y}^{37}\text{Y}^{38}\text{Y}$, and $^{124}\text{N}^{123}\text{Y}^{126}\text{N}$ mutant variants were chosen for further characterization. Similar to the wild-type GPDA, the addition of other monosaccharides than GlcN or the addition of the amino acid glycine did not result in any protein precipitation (Supplemental Fig. S10b–d). The GPDA mutant variants and the wild-type showed comparable enzymatic activity for up to 24 h exposure at standard reaction conditions (pH 8.0, 37 °C). However, the three most active mutant variants were less active when the enzymes were pre-incubated for more than 3 h at 65 °C (Supplemental Fig. S12). Although these differences in heat stability between the GPDA wild-type and mutant variants have only little consequence at the ambient temperatures used for the precipitation reaction, it may still be a contributing factor to the enhanced overall precipitation performance of each mutant variant.

The precipitation efficacy of $^{36}\text{F}^{37}\text{H}^{38}\text{L}$, $^{36}\text{Y}^{37}\text{Y}^{38}\text{Y}$, and $^{124}\text{N}^{123}\text{Y}^{126}\text{N}$ strongly depended on the concentration of GlcN, with no to little precipitation observed between 1 mM and 20 mM of GlcN (Fig. 4a). Strong precipitation was observed for samples containing 50, 100, and 200 mM of GlcN, and the limit of detection was determined to be between 10–20 mM of GlcN (Supplemental Fig. S13a–c). GPDA mutant $^{124}\text{N}^{123}\text{Y}^{126}\text{N}$ showed the fastest response of all tested variants, and protein precipitation started almost immediately upon the addition of GlcN. The structural comparison of the GPDA wild-type and mutant variants using AlphaFold revealed that the amino acid substitutions of all mutants led to a reduced size of the glucosamine-6-phosphate binding site (Fig. 4b). We speculate that these substitutions may facilitate the accommodation of a sterically smaller GlcN. Despite observing a clear difference in the precipitation behavior between the GPDA wild-type and mutant variants in the presence of GlcN, this effect can currently not be pinned down to a single amino acid substitution. Therefore, we presume that steric effects are the main cause for this functional changes. A comparison of the amino acid substitu-




Fig. 4 (a) Protein precipitation behavior of GPDA mutant variants and (b) visualization of the GlcN binding site of the GPDA wild-type and mutant variants protein models generated by AlphaFold.

tions showed a significant increase of the overall size for all mutants (wild-type $^{36}\text{G}^{37}\text{S}^{38}\text{T} = 263$ Da vs. mutant $^{36}\text{F}^{37}\text{H}^{38}\text{L} = 415$ Da vs. mutant $^{36}\text{Y}^{37}\text{Y}^{38}\text{Y} = 507$ Da; wild-type $^{124}\text{G}^{123}\text{I}^{126}\text{G} = 245$ Da vs. mutant $^{124}\text{N}^{123}\text{Y}^{126}\text{N} = 409$ Da), which further substantiated the presumption of a sterically guided precipitation effect.

CONCLUSIONS

In summary, we presented two previously undescribed methods for the detection of GlcN in aqueous solutions. The first method describes a one-step synthetic strategy for the synthesis of a fluorescent glucosamine derivative. This derivative possesses very unusual fluorescent properties, showing a massive Stokes shift of 88 nm, and might therefore be useful in tracing GlcN. This GlcN derivatization can be performed in a single step reaction and does not require any sample workup prior to HPLC analysis, and although this method allows the derivatization of small quantities of GlcN, a fluorescence detector is required for the detection of the analyte. The second method presented is based on the precipitation behavior of the GPDA protein in the presence of GlcN, and the generation and screening of engineered GPDA mutants resulted in the selection of three variants with increased properties. Although the detection limit for GlcN of this method is still relatively high (10–20 mM of GlcN), further mutational screens of GPDA are likely to result in the discovery of more sensitive mutant variants. Furthermore, no derivatization of GlcN is required prior to the analysis, and the precipitation can be either monitored by the naked eye or photometrically, and therefore enabling the development of high-throughput screens. We envisage that these methods will be a useful addition to the currently available toolbox for GlcN detection.

ACKNOWLEDGMENTS

This work was supported in parts by the National Natural Science Foundation of China (grant numbers 31471703, 31671854, and 31871754), and the 100 Foreign Talents Plan (grant number JSB2014012).

Conflict of interest

Josef Voglmeir is the Editorial Board members of Journal *Food Materials Research*. He was blinded from reviewing or making decisions on the manuscript. The article was subject to the journal's standard procedures, with peer-review handled independently of these Editorial Board members and their research groups.

Supplementary Information accompanies this paper at (<https://www.maxapress.com/article/doi/10.48130/FMR-2022-0019>)

Dates

Received 16 November 2022; Accepted 14 December 2022; Published online 30 December 2022

REFERENCES

- Uhde A, Youn JW, Maeda T, Clermont L, Matano C, et al. 2013. Glucosamine as carbon source for amino acid-producing *Corynebacterium glutamicum*. *Applied Microbiology and Biotechnology* 97:1679–87
- Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP. 2011. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. *Osteoarthritis and Cartilage* 19:375–80
- Nakamura H. 2011. Application of glucosamine on human disease—Osteoarthritis. *Carbohydrate Polymers* 84:835–39
- Coherent Market Insights. 2020. Glucosamine Market Analysis. *Report*. www.coherentmarketinsights.com/market-insight/glucosamine-market-4345 (Access on 2022/11/02)
- Bissett DL. 2006. Glucosamine: an ingredient with skin and other benefits. *Journal of Cosmetic Dermatology* 5:309–15
- Xing R, Liu S, Guo Z, Yu H, Li C, et al. 2006. The antioxidant activity of glucosamine hydrochloride *in vitro*. *Bioorganic & Medicinal Chemistry* 14:1706–9
- Bekesi JG, Molnar Z, Winzler RJ. 1969. Inhibitory effect of d-glucosamine and other sugar analogs on the viability and transplantability of ascites tumor cells. *BioMed Research International* 29:353–59
- Brasky TM, Lampe JW, Slatore CG, White E. 2011. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. *Cancer Causes & Control* 22:1333–42
- Friedman SJ, Skehan P. 1980. Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. *PNAS* 77:1172–76
- Krug E, Zweibaum A, Schulz-Holstege C, Keppler D. 1984. D-glucosamine-induced changes in nucleotide metabolism and growth of colon-carcinoma cells in culture. *Biochemical Journal* 217:701–8
- Liu B, Meng X, Li C, Gao Y, Li N, et al. 2011. Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. *Experimental & Molecular Medicine* 43:487–93
- Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, et al. 2014. D-Glucosamine supplementation extends life span of *Nematodes* and of ageing mice. *Nature Communications* 5:3563
- Shintani T, Kosuge Y, Ashida H. 2018. Glucosamine extends the lifespan of *Caenorhabditis elegans* via autophagy induction. *Journal of Applied Glycoscience* 65:37–43
- Lyu Y, Zheng F, Qiu C, Wang M, Wang D, et al. 2021. Heterologous expression of a thermostable chitinase from *Myxococcus xanthus* and its application for high yield production of glucosamine from shrimp shell. *Foods* 10:2808
- Lv YM, Laborda P, Huang K, Cai ZP, Wang M, et al. 2017. Highly efficient and selective biocatalytic production of glucosamine from chitin. *Green Chemistry* 19:527–35
- Haupt J, McMillan R, Wein C, Paget-Dellio S. 1999. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. *The Journal of Rheumatology* 26:2423–30
- Pouwels MJJ, Jacobs JR, Span PN, Lutterman JA, Smits P, et al. 2001. Short-term glucosamine infusion does not affect insulin sensitivity in Humans. *The Journal of Clinical Endocrinology & Metabolism* 86:2099–103
- Cheng R, Liu Y, Ou S, Pan Y, Zhang S, et al. 2012. Optical turn-on sensor based on graphene oxide for selective detection of D-glucosamine. *Analytical Chemistry* 84:5641–44
- Cooper CR, James TD. 2000. Synthesis and evaluation of D-glucosamine-selective fluorescent sensors. *Journal of the Chemical Society* 1:963–69
- Fujiwara T, Kubota K, Sato T, Matsuzawa T, Tada M, et al. 1990. N-[18F]fluoroacetyl-D-glucosamine: a potential agent for cancer diagnosis. *Journal of Nuclear Medicine* 31:1654–58

21. Tran TM, Alan Y, Glass TE. 2015. A highly selective fluorescent sensor for glucosamine. *Chemical Communications* 51:7915–18
22. Lin-Goerke JL, Robbins DJ, Burczak JD. 1997. PCR-based random mutagenesis using manganese and reduced dNTP concentration. *International Journal of Cancer* 23:409–12
23. Reetz MT, Wang L, Bocola M. 2006. Directed evolution of enantioselective enzymes: iterative cycles of CASTing for probing protein-sequence space. *Angewandte Chemie International Edition* 45:1236–41
24. Liu C, Li D, Liang YH, Li LF, Su XD. 2008. Ring-opening mechanism revealed by crystal structures of NagB and its ES intermediate complex. *Journal of Molecular Biology* 379:73–81
25. Elbing K, Brent R. 2002. Media preparation and bacteriological tools. *Current Protocols in Molecular Biology* 59:1–9
26. Shmueli MD, Hizkiahou N, Peled S, Gazit E, Segal D. 2017. Total proteome turbidity assay for tracking global protein aggregation in the natural cellular environment. *Journal of Biological Methods* 4:e69
27. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, et al. 2021. UCSF ChimeraX: structure visualization for researchers, educators, and developers. *Protein Science* 30:70–82
28. Hu ZX, Cheng C, Li YQ, Qi XH, Wang T, et al. 2022. Recombinant snail sialic acid aldolase is promiscuous towards aliphatic aldehydes. *ChemBiochem* 23:e202200074
29. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. 2004. UCSF Chimera—A visualization system for exploratory research and analysis. *Journal of Computational Chemistry* 25:1605–12
30. Cai Z, Wang W, Conway L, Huang K, Awad FN, et al. 2017. 1,3-Di(2-dipyridyl)propan-1,3-Dione—a new fluorogenic labeling reagent for milk oligosaccharides. *Pure and Applied Chemistry* 89:921–29
31. Cai ZP, Hagan AK, Wang MM, Flitsch SL, Liu L, et al. 2014. 2-Pyridylfuran: a new fluorescent tag for the analysis of carbohydrates. *Analytical Chemistry* 86:5179–86
32. Jackman LM, Lange BC. 1977. Structure and reactivity of alkali metal enolates. *Tetrahedron* 33:2737–69
33. Dey S, Jayaraman N. 2014. Glycosidic bond hydrolysis in septanosides: a comparison of mono-, di-, and 2-chloro-2-deoxy-septanosides. *Carbohydrate Research* 399:49–56
34. Davis TM, Lowary TL. 2000. Unexpected formation of glycals upon attempted C-alkylation of protected glycosylacetelylenes. *Carbohydrate Research* 324:210–17
35. Mukherjee A, Jayaraman N. 2012. 2,3-Unsaturated enoses. A Pummerer rearrangement route to sugar vinyl sulfides and synthesis of 3-deoxy-3-alkyl/arylsulfinyl pyranosides. *Tetrahedron* 68:8746–52
36. Qian J, Cao WG, Zhang H, Chen J, Zhu SZ. 2007. A novel and facile synthesis of 2, 3-dihydrofuran derivatives containing trifluoromethyl group. *Journal of Fluorine Chemistry* 128:207–10
37. Riemann I, Fessner WD, Papadopoulos MA, Knorst M. 2002. C-glycosides by aqueous condensation of β -dicarbonyl compounds with unprotected sugars. *Australian Journal of Chemistry* 55:147–54
38. Gorakshakar AC, Ghosh K. 2016. Use of lectins in immunohematology. *Asian Journal of Transfusion Science* 10:12–21
39. Dam TK, Talaga ML, Fan N, Brewer CF. 2016. Measuring multivalent binding interactions by isothermal titration calorimetry. *Methods in Enzymology* 567:71–95
40. Min YQ, Duan XC, Zhou YD, Kulinich A, Meng W, et al. 2017. Effects of microvirin monomers and oligomers on hepatitis C virus. *Bioscience Reports* 37:BSR20170015
41. Lindhorst TK, Dubber M. 2015. Octopus glycosides: multivalent molecular platforms for testing carbohydrate recognition and bacterial adhesion. *Carbohydrate Research* 403:90–97
42. Kuwabara N, Hu D, Tateno H, Makyio H, Hirabayashi J, et al. 2013. Conformational change of a unique sequence in a fungal galectin from *Agrocybe cylindracea* controls glycan ligand-binding specificity. *FEBS Letters* 587:3620–25



Copyright: © 2022 by the author(s). Published by Maximum Academic Press on behalf of Nanjing Agricultural University. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit <https://creativecommons.org/licenses/by/4.0/>.